News
03-15-2022, 04:48 PM
Stand Up To Cancer and Zentalis Pharmaceuticals, Inc. today announced that Zentalis will contribute $1 million to the SU2C Catalyst program to support research that investigates the use of certain small molecule inhibitors for treating a variety of cancer types.
More... (https://www.news-medical.net/news/20220315/Zentalis-contributes-241-million-to-SU2C-Catalyst-program-for-research-into-targeted-cancer-therapeutics.aspx)
More... (https://www.news-medical.net/news/20220315/Zentalis-contributes-241-million-to-SU2C-Catalyst-program-for-research-into-targeted-cancer-therapeutics.aspx)